Company news

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) news

Every Milestone Pharmaceuticals Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) news

Press releases & updates

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripa...

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) o...

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation...

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 2, 2026

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST Nasal Spray in Patients with PSVT

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST (etripamil) Nasal Spray in Patients ...

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients...

Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CAR...

Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scienti...

Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Adminis...

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European M...

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supr...

Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Hea...

Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

Milestone® Pharmaceuticals to Present at Upcoming Conferences

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warra...

Milestone Pharmaceuticals Announces Proposed Public Offering

Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

FDA Issues Complete Response Letter for Etripamil for PSVT

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024

Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals Refreshes Board of Directors

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness

Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologie...